GGrantIndex
← Leaderboards

Kenneth Cusi

University Of Texas Hlth Sci Ctr San Ant

Google Scholar ↗PubMed ↗ORCID ↗
$1,000,345
Attributed
$1,000,345
Total exposure
21
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $332.5K · FY2005–08
$500K$375K$250K$125K$0
'05
'06
'07
'08

Funding mix

By agency

NIH$1,000,345 · 21

By mechanism

M01$1,000,345 · 21

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Hlth Sci Ctr San Ant

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchObesitySourceResourcesDiabetes Mellitus, Non-Insulin-DependentComputer Retrieval Of Information On Scientific Projects DatabaseInstitutionUnited States National Institutes Of HealthResearch PersonnelGrantFundingNoninsulin Dependent Diabetes MellitusInsulinHuman SubjectInsulin Sensitivity /ResistanceFree Fatty AcidsGlucoseInsulin ResistanceGlucose MetabolismFamily History OfPlasmaPathogenesisPublic Health Medicine (Field)Lipids

Grant awards (28)

EFF BASAL/PREMEAL INS STRAT (DETEMIR/ASPART) TO IMP INS SECRETION/ACTION IN T2D$16,205
M01 · FY2008 · RR · contact PI
EFFECT OF ACQUIRED INSULIN RESISTANCE (DEXAMETHASONE-INDUCED) ON INSULIN SECRETN$5,324
M01 · FY2008 · RR · contact PI
NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS$2,489
M01 · FY2008 · RR · contact PI
PROT 2: ACQUIRED VS GENETIC DETERMINANTS OF BETA-CELL LIPOTOXICITY IN MAS$1,765
M01 · FY2008 · RR · contact PI
BETA-CELL LIPOTOXICITY IN MAS: PROT 1: EFFECT OF GLUCOSE TOXICITY ON B-CELL FUNC$174
M01 · FY2008 · RR · contact PI
EFF BASAL/PREMEAL INS STRAT (DETEMIR/ASPART) TO IMP INS SECRETION/ACTION IN T2D$133,407
M01 · FY2007 · RR · contact PI
BETA-CELL LIPOTOXICITY IN MA: PROT 1: EFFECT OF GLUCOSE TOXICITY ON B-CELL FUNCT$105,146
M01 · FY2007 · RR · contact PI
ACQUIRED VS GENETIC DETERMINANTS OF BETA-CELL LIPOTOXICITY IN MEXICAN AMERIC$63,586
M01 · FY2007 · RR · contact PI
ROLE OF PIOGLITAZONE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS$25,767
M01 · FY2007 · RR · contact PI
ROLE OF INSULIN RESISTANCE AND CV RISK IN CORONARY ARTERY DISEASE IN DIABETES$3,325
M01 · FY2007 · RR · contact PI
EFFECT OF ACQUIRED INSULIN RESISTANCE (DEXAMETHASONE-INDUCED) ON INSULIN SECRETN$1,247
M01 · FY2007 · RR · contact PI
BETA-CELL LIPOTOXICITY IN MEXICAN-AMERICANS PREDISPOSED TO TYPE 2 DIABETES$109,267
M01 · FY2006 · RR · contact PI
ACQUIRED VS GENETIC DETERMINANTS OF BETA-CELL LIPOTOXICITY IN MEXICAN AMERIC$44,153
M01 · FY2006 · RR · contact PI
ROLE OF PIOGLITAZONE IN THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS$43,707
M01 · FY2006 · RR · contact PI
ROLE OF INSULIN RESISTANCE AND CV RISK IN CORONARY ARTERY DISEASE IN DIABETES$10,258
M01 · FY2006 · RR · contact PI
ROLE OF PIOGLITAZONE IN THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS$191,700
M01 · FY2005 · RR
BETA-CELL LIPOTOXICITY IN MEXICAN-AMERICANS PREDISPOSED TO TYPE 2 DIABETES$58,469
M01 · FY2005 · RR
ROLE OF INSULIN RESISTANCE AND CV RISK IN CORONARY ARTERY DISEASE IN DIABETES$16,294
M01 · FY2005 · RR
Pioglitazone in Therapy of Nonalcoholic Steatohepatitis$152,882
M01 · FY2004 · RR
FFA Induced Abnormality in Early Steps of Insulin Action$15,180
M01 · FY2004 · RR
FENOFIBRATE--GLUCOSE/LIPID METABOLISM IN NIDDM$0
M01 · FY2002 · RR
FFA METABOLISM/FAT STRUCTURE AND PATHOGENESIS OF NIDDM$0
M01 · FY2002 · RR
FFA METABOLISM/FAT STRUCTURE AND PATHOGENESIS OF NIDDM$0
M01 · FY2002 · RR
FENOFIBRATE--GLUCOSE/LIPID METABOLISM IN NIDDM$0
M01 · FY2002 · RR
FFA METABOLISM/FAT STRUCTURE AND PATHOGENESIS OF NIDDM$0
M01 · FY2001 · RR
FENOFIBRATE--GLUCOSE/LIPID METABOLISM IN NIDDM$0
M01 · FY2001 · RR
FFA METABOLISM/FAT STRUCTURE AND PATHOGENESIS OF NIDDM$0
M01 · FY2000 · RR
FENOFIBRATE--GLUCOSE/LIPID METABOLISM IN NIDDM$0
M01 · FY2000 · RR